Alkem Laboratories Ltd (ALKEM) is currently trading at 5,663.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alkem Laboratories Limited is a leading pharmaceutical company based in Mumbai, India, specializing in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Its primary offerings include branded generics, generic drugs, and active pharmaceutical ingredients (APIs). The company reported a robust 17% revenue growth in Q2 FY26, with EBITDA margins improving to 23%. It has shown significant growth across India, the US, and international markets, largely driven by new product launches and strong performance in key therapeutic areas. Alkem has become the number one company in the Acute segment within the Indian Pharmaceutical Market (IPM) for Q2 FY26 and outperformed industry growth in important therapy areas such as anti-infectives and gastrointestinal disorders. The company's growth strategy is supported by a focus on innovation and a large pipeline of ANDA filings in the US, with 187 ANDAs submitted and 163 approved as of September 2025. This positions Alkem as a strong player in the U.S. generic market. Investment in new business areas like biologics and the establishment of manufacturing facilities for biosimilars underline Alkem's strategic expansion efforts, enhancing its competitive edge in both domestic and international markets.

Over the past 52 weeks, Alkem Laboratories Ltd has traded between a low of ₹4,498.90 and a high of ₹5,933.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alkem Laboratories Ltd has a market capitalization of approximately 67,969.12. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alkem Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.81 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Alkem Laboratories Ltd (ALKEM) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 67,969.12 Cr, Alkem Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alkem Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alkem Laboratories Ltd is 28.81. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Alkem Laboratories Ltd pays dividends with a current dividend yield of 0.79%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Alkem Laboratories Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.